Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst day in a long, long time. On May 1, Lilly reported Q1 earnings. Afterwards ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

Shares of Eli Lilly ( LLY -10.61%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

Eli Lilly stock trades above all major moving averages, indicating a strongly bullish technical trend. Analysts see 3% upside, but momentum indicators suggest the rally could have more room to run.

And if those prospects are strong, it wouldn't be surprising to see the healthcare stock take off on the developments. Eli Lilly stock could prove to be a no-brainer buy right now It has been a ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.